Background
Autoinflammatory diseases (AIDs) comprise a heterogeneous group of genetically and/or clinically defined conditions characterized by unprovoked systemic inflammation causing fever episodes and inflammatory organ manifestations [
1,
2]. Mutations in inflammatory genes result in constitutionally raised levels of secreted pro-inflammatory cytokines such as Interleukin-1 (IL-1) [
3]. AIDs carry a significant mortality and morbidity including failure to thrive, hearing loss and renal failure. While Familiar Mediterranean Fever (FMF) can be found with a high prevalence of 1/1000 in several Mediterranean populations [
4], other AIDs including Cryopyrin-Associated Periodic Syndrome (CAPS) [
5,
6], TNF Receptor-Associated Periodic Syndrome (TRAPS) [
7] and Mevalonate Kinase Deficiency Syndrome (MKD)/ Hyper-IgD Syndrome (HIDS) [
8] are rare and have an incidence of less than 1/1.000.000 [
9].
Diagnosing a rare AID mandates the recognition of characteristic clinical findings. Diagnostic criteria are currently only available for CAPS [
10]; classification criteria have recently been validated for FMF, TRAPS, MKD, CAPS and PFAPA addressing genetic and clinical criteria [
11,
12]. A molecular genetic confirmation of a rare AID is desirable, yet not always possible. Increased awareness of clinicians and access to genetic testing has significantly reduced the delay to diagnosis in many countries [
4]. However, the variability of disease activity has not been addressed in diagnostic or classification criteria. Atypical clinical phenotypes and late-onset subtypes associated with somatic mutations can be seen [
13].
The optimal day-to-day management of rare AIDs remains challenging. Traditional immunosuppressive medications such as prednisone often have limited effect and may even shorten intervals between flares [
14]. Targeted inhibition of specific pro-inflammatory cytokines is commonly required. Early effective treatment of the underlying systemic inflammatory process prevents fever episodes and organ damage [
15,
16]. Significant variations in care impact on patient outcomes [
17]. Access to effective medications varies between countries; coverage of the frequently prohibitive drug costs remains a major barrier [
18].
In 2015, the Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) initiative set out to improve the management of patients with rheumatic diseases including AIDs [
19]. SHARE investigators synthesized the published evidence and developed management recommendations. Important guiding principles were established; optimal treatment selection and monitoring concepts were defined. However, the effective implementation of evidence-based treatment recommendations into clinical practice mandates development of consensus protocols. Entry criteria for distinct levels of disease activity, risk factors for adverse outcomes and sensible timelines for evaluating outcomes have to be defined.
The PRO-KIND (PROjekte zur Klassifikation, Überwachung und Therapie in der KINDerrheumatologie, Projects for the classification, monitoring and therapy in pediatric rheumatology) initiative is a sub-committee of the German Society for Pediatric Rheumatology (GKJR). The national PRO-KIND initiative addresses the urgent need to improve quality of care and outcome of children and adolescents living with rheumatic conditions by standardization and effective implementation of evidence-based therapies and thereby decreasing variation in care [
20‐
22].
The aims of the PRO-KIND initiative for CAPS/TRAPS/MKD/HIDS were 1) to establish consensus-based statements for the diagnosis and management and 2) to establish national treat-to-target consensus treatment plans (CTPs) for CAPS, TRAPS and MKD/HIDS suitable for implementation. A separate working group for FMF was established [
23].
Discussion
The GKJR PRO-KIND initiative developed the first evidence-based treat-to-target CTPs for autoinflammatory diseases defining treatment targets and integrating patient-centred monitoring of disease activity. The CTPs were established to define standards for the heterogeneous group of autoinflammatory diseases including clinical phenotyping, relevant laboratory tests and genetic testing. They aim to enable and harmonize continuous monitoring of disease activity, provide guidance for clinical examination, laboratory tests and psychosocial care and establish treat-to-target strategies for management to improve health related quality of life and prevent damage.
At diagnosis, the patient’s individual disease activity in addition to the overall AID diagnosis should guide initial management decisions. The disease phenotype is highly variable and can be independent of the presence or type of pathogenic gene variant. In CAPS, the stratification into distinct phenotypes is widely accepted; however, also in patients with TRAPS and MKD/HIDS disease phenotypes can vary dramatically [
30,
34]. The individual AID disease activity at diagnosis and at each subsequent evaluation is estimated regarding the extent and severity of clinical symptoms, previous flare duration and frequency plus level of inflammatory markers at time of diagnosis and during flares. These estimates are captured in both patient- and physician derived validated instruments.
Stratified treatment approaches are increasingly made available for childhood rheumatic diseases. Disease subtype, risk factors at onset and disease activity are the foundation for the traditional stratified ACR juvenile idiopathic arthritis (JIA) treatment recommendations [
49,
50]. Similarly, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) CTPs for juvenile dermatomyositis stratify approaches based on subtype and disease activity [
51,
52]. In contrast, for systemic lupus erythematosus (SLE), type and extent of major organ involvement such as type of lupus nephritis typically drives treatment selections. The SHARE guidelines for childhood-onset SLE recommended different treatment regimens for haematological disease, neuropsychiatric involvement and nephritis further differentiating in histological classes [
53,
54].
The PRO-KIND CAPS/TRAPS/MKD/HIDS CTP approach follows the model set by Swart [
55] and Consolaro [
56] for JIA. The composite patient and physician-partnered disease activity instrument Juvenile Arthritis Disease Activity Score (JADAS) [
57] was integrated into clinical care as the anchor of treatment decision making [
50]. This has facilitated impactful treat-to-target strategies resulting in better outcomes [
55]. The proposed German PRO-KIND consensus statements and resulting CTPs represent an important step forward beyond disease classification-based recommendations for patients with AIDs [
19].
The definition of therapeutic targets, the continuous integration of disease activity measurements and the clinical evaluation at defined time points are the basis for the German PRO-KIND CTPs. Therefore, all treatment decisions follow the treat-to-target concept and enable precision health care for children. Continuous disease activity monitoring using evaluated instruments and adjustment of treatment intensity are important to avoid over- or under-treatment. The integration of patient perspective through AIDAI, physician rating of disease activity and assessment of inflammatory markers was utilized in the initial approval studies for IL-1 inhibition in AIDs [
26,
27,
46]. While there is no mathematical formula to best integrate the different components, concordant estimates of disease activity clearly support treatment decisions to adjust therapies. Discordant estimates are equally important, as they mandate further evaluations.
Several AID real-life series have focussed on the frequency of achieving remission and the requirement for dose adjustments. Young children with CAPS, in particular those with the severe phenotype NOMID and high disease activity, require much higher starting doses of IL-1-inhibitors and frequent dose increases [
17,
58]. This treat-to-target approach successfully controls disease activity and can prevent organ damage in patients with AIDs [
59]. In contrast, there is a very mild AID phenotype with limited disease activity: some CAPS patients experience significantly fewer symptoms during warm seasons, TRAPS patients may have very infrequent episodes of clinically active disease [
60]. In addition, the risk of organ damage may differ dramatically between AID patients as demonstrated for the risk of hearing loss in CAPS [
40].
There are several limitations to the study. 1) The PRO-KIND CAPS/TRAPS/MKD/HIDS expert working group consisted of only 12 members, which limited the scale and scope of contributing experiences. However, the three diseases are bordering on ultra-rare (≤1/1Mio) frequency, limiting the continuous exposure to patients to experts from larger German/Austrian AID centres, all of whom participated in the study. 2) The proposed on-demand strategy for mild phenotypes is supported by low level evidence. However, in clinical practice this approach is utilized in Germany and had to be included as one of the treatment arms in order to allow for inclusion of all patients into CTP-guided care. 3) The generalizability of the German CAPS/TRAPS/MKD/HIDS CTPs is limited to countries with unrestricted, mainly publicly funded access to treatment. However, many of the European countries can potentially follow the proposed paths. The evaluation of the CTPs may enable the community to rapid access to evidence based biologic therapies.
PRO-KIND advances the standardization of diagnosis and management of childhood rheumatic diseases. Publicly available, evidence-based guidance statements and CTPs can decrease variation in care, in particular in rare rheumatic diseases as individual physician preferences may not weigh as heavy as in more common diseases. The engagement and support of the German paediatric rheumatology community was critical to develop the statements, algorithms and CTPs. The integration of the developed framework into clinical practice is the critical next step.
Ultimately the evaluation of these real-life data with comparative effectiveness studies will define if the PRO-KIND approach can optimize health outcomes for children with rheumatic diseases in Germany and beyond.
Competing interests
S.H. received honoraria from Novartis Pharma for Advisory Board attendance.
E.L. received speaker honoraria from Novartis and SOBI and funding for the AID-registry by the Federal Ministry of Education and Research (BMBF: 01GM08104, 01GM1112D, 01GM1512D).
G.H. received speaker honoraria from Novartis, MSD, Bayer, Bristol-Myers, Sobi, Boehringer and Chugai and received research grants from AbbVie, Chugai, Novartis, Pfizer, Roche and MSD.
D.H. received speaker honoraria from Novartis Pharma.
N.R. received research grants, travel grants for Advisory Board attendance and speaker honoraria from Novartis.
A.J. has no financial disclosures.
A.R.-W. received research grants, travel grants for Advisory Board attendance and speaker honoraria from Novartis.
G.E. was partially funded through the Margarete Mueller-Bull Stiftung and a research grant of Novartis Pharma. G.E. also received speaker honoraria from Novartis Pharma.
M.P. received speaking honoraria from Novartis, MSD, Pfizer, SOBI and Chugai and received research grants from Novartis, SOBI, Pfizer and Chugai.
J.B. received speaker’s bureaus or consulting fees from AbbVie, Novartis, and Pfizer.
S.B. received speaker honoraria from Novartis and SOBI.
J.B.K.-D. performed clinical studies with and received educational, research and centre grants and honoraria from Novartis, AbbVie and SOBI.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.